Science

Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy

Al-Ola Abdallah/LinkedIn

May 1, 2025, 10:25

Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy

Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared an article by Donald Waddell, et al. on X:

“Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy.

TPO-RAs did not increase the rate of thrombocytopenia resolution relative to supportive care.
Adverse effects requiring therapy modification related to TPO-RAs occurred in 25% of patients.
The financial toxicity associated with TPO-RAs was roughly $87,000.”

Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy.

Authors: Donald Waddell, Jennifer Collins, Sarvnaz Sadrameli

You can Read the Full Article on Journal of Transplantation and Cellular Therapy.

Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy

More posts featuring Al-Ola A Abdallah.

Al-Ola A Abdallah cancer Donald Waddell fight against cancer Global fight against cancer Jennifer Collins OncoDaily Oncology Plasma Cell disorder program Sarvnaz Sadrameli T-cell therapy Thrombocytopenia Thrombopoietin TPO-RAs transplantation and cellular therapy University of Kansas Medical Center

Vinay Prasad Rejoins FDA Days After Exit

New Paper Alert: Safety and Outcomes of T-DXd Retreatment After Grade 1 ILD Recovery

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Tyler Seibert: 10-year Results of FLAME Trial is Out Now